Aromatase Inhibitor Drug Class Market To Reach USD$ 6.7 Billion By 2033 Growth Drivers, Forecast & Industry (2026). EINPresswire/ -- Market Size and Growth (2026) According to DataM Intelligence, the ...

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase ...

December 9, 2010 (UPDATED December 10, 2010) (San Antonio, Texas) — The use of aromatase inhibitors for any length of time by postmenopausal women with breast cancer is associated with a significant ...

The FDA approval was based on NATALEE, a randomized (1:1), open-label, multicenter, multinational trial in adults of any sex or menopausal status with hormone receptor–positive, HER2-negative stage II ...

DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.

Boston, MA, and San Francisco, CA - The aromatase inhibitors have revolutionized breast-cancer treatment by providing a more effective alternative to tamoxifen. However, Drs David T Felson (Boston ...

An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for ...

Kisqali combined with an aromatase inhibitor improved iDFS in hormone receptor-positive, HER2-negative early breast cancer, with a 30% risk reduction in DDFS and distant recurrence-free survival. The ...

Aromatase inhibitors (AIs) represent a cornerstone in the treatment of oestrogen receptor–positive breast cancer, particularly among postmenopausal women. Although these drugs have substantially ...

Image by the US National Institutes of Health, CC 3.0 Image by the US National Institutes of Health, CC 3.0 A powerful new drug for advanced breast cancer can be used to treat emerging resistance to ...

Phase 3 ELAINE-3 study is currently investigating lasofoxifene as a potential therapy for ESR1-mutated breast cancer COLUMBUS, Ohio, June 10, 2024 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a ...